Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Fehr

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
Nature|August 9, 2001
Pattern of focal gamma-bursts in chess playersO Amidzic, H J Riehle, T Fehr, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|November 9, 2000
MEG gamma band activity in schizophrenia patients and healthy subjects in a mental arithmetic task and at restJ Kissler, M M Müller, T Fehr, et al.
Transplantation|September 7, 2001
Leflunomide-mediated suppression of antiviral antibody and Tcell responses: differential restoration by uridineD D Pinschewer, A F Ochsenbein, T Fehr, et al.
Biological Psychiatry|August 31, 2001
Source distribution of neuromagnetic slow waves and MEG-delta activity in schizophrenic patientsT Fehr, J Kissler, S Moratti, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 1997
Correlation of tolerogenicity of a viral antigen with its immunogenicityM F Bachmann, T Fehr, G Freer, et al.
International Archives of Allergy and Applied Immunology|January 1, 1988
Protein kinase C activators of the teleocidin family decrease the IgE-binding capacity of rat basophilic leukemia cellsC Gavériaux, T Fehr, E Montecino-Rodriguez, et al.
The Canadian Nurse|March 1, 1995
Discontinuation of lifesupportL Pronger, T Fehr, P Poulter-Friesen, et al.
Immunological Reviews|November 28, 2001
CD4+CD25+ regulatory cells in acquired MHC toleranceE H Field, D Matesic, S Rigby, et al.
Cellular Immunology|March 15, 1996
T-independent activation of B cells by vesicular stomatitis virus: no evidence for the need of a second signalT Fehr, M F Bachmann, H Bluethmann, et al.
Clinical Nephrology|February 11, 2009
Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipientsA-C Grimmelt, C D Cohen, T Fehr, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Nature|August 9, 2001
Pattern of focal gamma-bursts in chess playersO Amidzic, H J Riehle, T Fehr, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|November 9, 2000
MEG gamma band activity in schizophrenia patients and healthy subjects in a mental arithmetic task and at restJ Kissler, M M Müller, T Fehr, et al.
Transplantation|September 7, 2001
Leflunomide-mediated suppression of antiviral antibody and Tcell responses: differential restoration by uridineD D Pinschewer, A F Ochsenbein, T Fehr, et al.
Biological Psychiatry|August 31, 2001
Source distribution of neuromagnetic slow waves and MEG-delta activity in schizophrenic patientsT Fehr, J Kissler, S Moratti, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 1997
Correlation of tolerogenicity of a viral antigen with its immunogenicityM F Bachmann, T Fehr, G Freer, et al.
International Archives of Allergy and Applied Immunology|January 1, 1988
Protein kinase C activators of the teleocidin family decrease the IgE-binding capacity of rat basophilic leukemia cellsC Gavériaux, T Fehr, E Montecino-Rodriguez, et al.
The Canadian Nurse|March 1, 1995
Discontinuation of lifesupportL Pronger, T Fehr, P Poulter-Friesen, et al.
Immunological Reviews|November 28, 2001
CD4+CD25+ regulatory cells in acquired MHC toleranceE H Field, D Matesic, S Rigby, et al.
Cellular Immunology|March 15, 1996
T-independent activation of B cells by vesicular stomatitis virus: no evidence for the need of a second signalT Fehr, M F Bachmann, H Bluethmann, et al.
Clinical Nephrology|February 11, 2009
Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipientsA-C Grimmelt, C D Cohen, T Fehr, et al.
Pageof 7